Current Report Filing (8-k)

Date : 08/13/2018 @ 12:34PM
Source : Edgar (US Regulatory)
Stock : Enzon Pharmaceuticals, Inc. (QX) (ENZN)
Quote : 0.23  0.0 (0.00%) @ 12:52PM

Current Report Filing (8-k)

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 9, 2018

 

ENZON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

 

Delaware
(State or other jurisdiction of
incorporation)

001-36435

(Commission File Number)

22-2372868
(IRS Employer Identification No.)

 

20 Commerce Drive (Suite 135), Cranford, New Jersey
(Address of principal executive offices)
07016
(Zip Code)

 

(732) 980-4500
(Registrant’s telephone number, including area code)

 

Not Applicable
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

The 2018 annual meeting of stockholders of Enzon Pharmaceuticals, Inc. (the “Company”) was held on August 9, 2018. At the 2018 annual meeting of stockholders, the Company’s stockholders voted on the following matters as described in the Company’s proxy materials: (1) the election of three directors, each for a one-year term expiring at the Company’s next annual meeting of stockholders and until such director’s successor is elected and qualified, (2) the ratification of the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018 and (3) the approval, on an advisory basis, of the compensation of the Company’s named executive officers. A total of 36,439,678 shares of common stock were present or represented by proxy at the 2018 annual meeting of stockholders, representing approximately 82.4% of the total shares of common stock entitled to vote at the 2018 annual meeting of stockholders.

 

1. Election of Directors – The Company’s stockholders elected each of the following individuals as a director for a one-year term expiring at the Company’s next annual meeting of stockholders and until such director’s successor is elected and qualified, as set forth below:

 

Nominee

Votes For

Votes Against

Abstentions

Broker Non-Votes

Jonathan Christodoro 12,393,843 310,706 32,047 23,703,082
Odysseas Kostas, M.D. 12,363,767 341,469 31,360 23,703,082
Jennifer McNealey 12,366,108 338,886 31,602 23,703,082

 

2. Ratification of the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018 – This proposal was approved as set forth below:

 

Votes For

Votes Against

Abstentions

35,408,410 814,759 216,509

 

3. Approval, on an advisory basis, of the compensation of the Company’s named executive officers – This proposal was approved as set forth below:

 

Votes For

Votes Against

Abstentions

Broker Non-Votes

11,957,462 656,347 122,787 23,703,082

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ENZON PHARMACEUTICALS, INC.  
  (Registrant)  
     
Date: August 13, 2018 By: /s/ Andrew Rackear  
 

Name:

Andrew Rackear

 
  Title: Chief Executive Officer and Secretary  

 

 

Enzon Pharmaceuticals, Inc. (USOTC:ENZN)
Historical Stock Chart

1 Year : From Oct 2018 to Oct 2019

Click Here for more Enzon Pharmaceuticals, Inc. Charts.

Enzon Pharmaceuticals, Inc. (USOTC:ENZN)
Intraday Stock Chart

Today : Friday 18 October 2019

Click Here for more Enzon Pharmaceuticals, Inc. Charts.

Latest ENZN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.